

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Henry Ford Health Genesys Hospital</p> <p>2. One Genesys Parkway Grand Blanc, MI 48439</p>	<p>In accordance with letter dated November 17, 2025,</p> <p>3. License No.: 21-26740-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: October 31, 2037</p> <p>5. Docket No.: 030-34188 Reference No.:</p>
--	---	--

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.
D. Yttrium-90 permitted by 10 CFR 35.1000	D. Microspheres (BWXT Medical Ltd., Model TheraSphere)	D. 540 millicuries per vial and 2 curies total	D. For medical use in permanent manual brachytherapy using BWXT Medical Ltd. Model TheraSphere Y-90 Glass Microsphere System as permitted by 10 CFR 35.1000.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-26740-01

Docket or Reference No.:
030-34188

Amendment No. 27

- | | | | |
|---|--|---|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>E. Yttrium-90 permitted by 10 CFR 35.1000</p> | <p>7. Chemical and/or physical form</p> <p>E. Microspheres (Sirtex Wilmington, LLC, Model SIR-Spheres)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>E. 540 millicuries per vial and 2 curies total</p> | <p>9. Authorized use</p> <p>E. For medical use in permanent manual brachytherapy using Sirtex Medical Model SIR-Spheres microspheres and delivery system permitted by 10 CFR 35.1000.</p> |
|---|--|---|---|



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-26740-01

Docket or Reference No.:
030-34188

Amendment No. 27

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities located at One Genesys Parkway, Grand Blanc, Michigan, 48439.
11. The Radiation Safety Officer (RSO) for this license is Karl F. Kado, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

<u>Authorized User (M.D.,D.O.,etc.)</u>	<u>Material and Use</u>
Mohammed S. Ibrahim Alagha, M.D.	10 CFR 35.100,10 CFR 35.200
Steven D. Brooks, D.O.	10 CFR 35.100,10 CFR 35.200
Ahmed Mohamed El-Sabbagh, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to oral administration of sodium iodide I-131)
Roger L. Gonda, Jr., M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Khaled Hammoud, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)
Reham Haroun, M.D.	10 CFR 35.1000 (limited to Yttrium-90 SIR-Spheres and TheraSpheres)
Karl F. Kado, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to oral administration of sodium iodide I-131)
Vikram Aroor Kinni, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Shehbaz Hasan Shaikh, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries),10 CFR 35.1000 (limited to Y-90 TheraSphere microspheres)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License No.: 21-26740-01

Docket or Reference No.:
030-34188

Amendment No. 27

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and applicable guidance updates for 10 CFR 35.1000 uses. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Letter dated April 22, 2022 (ML22116A075)
- B. Letter dated May 11, 2022 (ML22132A052)
- C. Letter dated January 12, 2023 (ML23017A103)
- D. Letter dated January 30, 2023 (ML23033A062)
- E. Letter dated July 2, 2024 (ML24205A225)
- F. Letter dated July 30, 2024 (ML24214A055)
- G. Letter dated November 17, 2025 (ML25321A455)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: February 3, 2026By: _____
Laura B. Cender
Region 3